Organon (OGN) is a potential acquisition target by India's Sun Pharmaceutical Industries, Germany's Grunenthal, and private equity firms, Bloomberg reported Thursday, citing unnamed people familiar with the matter.
The companies are reportedly consulting with advisers on potential binding bids for Organon to be submitted in the coming weeks, the report said.
The New Jersey-based women's healthcare company was spun off from Merck (MRK) in 2021, the report said.
Organon, Sun, and Grunenthal, didn't immediately respond to MT Newswires' request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Comments